The following is a summary of “Identification of molecular clusters and a risk prognosis model for diffuse large B-cell ...

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier ...

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi ® ...

is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autologous stem cell transplantation (ASCT).

It is a possible treatment for large B-cell lymphoma (diffuse large B‑cell, high-grade B‑cell, primary mediastinal large B-cell and follicular grade 3B) in adults when: the cancer has: stopped ...

Minjuvi ® in combination with lenalidomide, followed by Minjuvi ® monotherapy, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma ... the ...

Diffuse large B cell lymphoma (DLBCL) is cancer involving B cells. Under the microscope, the cells look just like the cancerous T cells found in anaplastic large cell lymphoma (ALCL). Both of these ...

What Is B-Cell Lymphoma? B-cell lymphoma is a cancer that ... Common side effects include: Diarrhea Nausea Fatigue Fever Low neutrophil levels (a type of white blood cell) You don’t have to ...

B.C. scientists are sounding the alarm over low measles vaccination rates in certain parts of the province. The B.C. Centre for Disease Control (BCCDC) provides stats on vaccination rates and it ...

trials for relapsed/refractory large B-cell lymphoma, a type of non-Hodgkin lymphoma, and in the ALPHA3 trial (NCT06500273) in patients with a low disease burden who have received cema-cel as ...